MCAS Symptoms: Recognizing Mast Cell Activation Syndrome Across Every Body System

Mast cell activation syndrome (MCAS) causes recurring symptoms in two or more organ systems at once, most often the skin, gut, cardiovascular system, lungs, and nervous system, triggered by everyday stimuli like heat, exercise, or certain foods rather than a true allergen, according to the 2019 consensus diagnostic criteria described by Valent and colleagues.

What Are Mast Cells and What Goes Wrong in MCAS?

Mast cells are immune sentinel cells positioned throughout your body, concentrated in tissues that interface with the outside world: skin, gut lining, respiratory tract, and around blood vessels and nerves. They are packed with granules containing over 200 chemical mediators, including histamine, tryptase, prostaglandins, leukotrienes, cytokines, and heparin [1].

In a healthy immune system, mast cells degranulate (release their contents) in response to genuine threats: parasitic infections, venom, tissue injury. In mast cell activation syndrome, these cells become hyperreactive. They degranulate in response to triggers that should not provoke an immune response: temperature changes, certain foods, stress, vibration, fragrances, or even exercise [2].

The result is a condition that can produce symptoms in virtually any organ system, at unpredictable times, with variable severity. This variability is a hallmark of MCAS and one reason it takes an average of 10 years from symptom onset to diagnosis.

Clinicians also refer to this condition as mast cell activation disorder (MCAD) or, when no other explanation is found, idiopathic MCAS. Whatever the label, the defining feature stays the same: mast cells firing in response to ordinary stimuli and producing symptoms across the skin, gut, heart, lungs, and nervous system at once.

MCAS vs. Mastocytosis: An Important Distinction

These two conditions are often confused but differ fundamentally:

• Mastocytosis involves a clonal proliferation of mast cells (there are literally too many of them). It is driven by mutations in the KIT gene (usually D816V) and can be detected by bone marrow biopsy. Systemic mastocytosis is relatively rare, affecting roughly 1 in 10,000 people [3].
• MCAS involves normal or near-normal numbers of mast cells that are hyperreactive. The problem is not quantity but behavior. MCAS is far more common than mastocytosis, though exact prevalence remains debated, with estimates suggesting it may affect up to 17% of the population in some form [4].

Treatment strategies overlap (both conditions respond to mast cell stabilizers and antihistamines), but the diagnostic workup and prognosis differ significantly.

Some clinicians use the broader term mast cell activation disease to cover both conditions along with monoclonal mast cell activation syndrome, a variant where KIT mutations are present without meeting the full criteria for mastocytosis.

Symptoms by Organ System

MCAS can produce symptoms in the skin, gastrointestinal tract, cardiovascular system, nervous system, respiratory tract, and musculoskeletal system, often several at once during a flare. The sections below cover each system in turn, using the entity and attribute detail clinicians look for when they evaluate a patient for mast cell activation syndrome.

Skin

The skin is one of the most mast cell-dense tissues in the body, making skin symptoms among the most common and visible manifestations of MCAS:

• Flushing: Episodic redness, warmth, and sometimes burning of the face, neck, and chest. Flushing can last minutes to hours and is often triggered by heat, alcohol, stress, or spicy foods. It differs from normal blushing in its intensity, duration, and the burning quality that often accompanies it [5].
• Urticaria (hives): Raised, itchy welts that appear suddenly and may migrate across the body. In MCAS, hives can occur without any identifiable external allergen.
• Dermatographism: The ability to “write” on the skin with light pressure and have the marks remain as raised, red welts for minutes to hours. Present in roughly 5% of the general population but is significantly more common in MCAS.
• Pruritus (itching): Generalized itching without a rash. Can be severe enough to disrupt sleep.
• Angioedema: Deep swelling of the skin, often around the eyes, lips, or extremities. Unlike hives (which are superficial), angioedema involves deeper tissue layers and can be alarming when it affects the face.

Gastrointestinal

GI symptoms are present in 60-80% of MCAS patients and are frequently the most disabling [6]:

• Abdominal cramping and pain: Often episodic, sometimes severe, and not always related to meals.
• Nausea: Can be chronic and low-grade or sudden and intense. Sometimes accompanied by vomiting.
• Diarrhea: May be watery or loose, sometimes alternating with constipation. Histamine stimulates gastric acid secretion and increases intestinal motility.
• Bloating: Can be significant. The overlap with SIBO is real, as mast cell activation in the gut can impair motility and predispose to bacterial overgrowth.
• Gastroesophageal reflux: Histamine stimulates parietal cells to produce stomach acid via H2 receptors. Chronic acid overproduction from mast cell activation can cause persistent reflux that does not fully respond to standard PPI therapy.
• Food intolerances: Patients often report an expanding list of food sensitivities. This is not classical food allergy (IgE-mediated) but rather mast cell-mediated reactions to food components, particularly histamine-rich foods, salicylates, and certain additives.

The overlap between MCAS and irritable bowel syndrome is substantial enough that many patients carry an irritable bowel syndrome diagnosis for years before mast cell activation is recognized. A structured SIBO guide can help sort out how much of the gut picture is mast cell driven versus a separate motility or bacterial overgrowth issue.

Cardiovascular

• Tachycardia: Rapid heart rate, often postural (worse when standing). Histamine acts on H1 and H2 receptors in the heart to increase heart rate. The overlap with POTS is common and well-documented [7].
• Hypotension: Histamine causes vasodilation, which can drop blood pressure. Patients may feel lightheaded, dizzy, or faint, especially when standing.
• Presyncope and syncope: Near-fainting or actual fainting episodes during severe mast cell activation flares.
• Chest pain: Can result from coronary artery spasm (Kounis syndrome, a mast cell-mediated phenomenon) or from esophageal spasm triggered by mast cell mediators.

Because histamine-driven tachycardia and hypotension overlap so heavily with postural orthostatic tachycardia syndrome, many MCAS patients also carry a POTS diagnosis. The POTS guide on this site walks through how that overlap is evaluated separately from mast cell testing.

Neurological

• Brain fog: Difficulty concentrating, word-finding problems, and short-term memory impairment. This is one of the most commonly reported and most frustrating MCAS symptoms. Histamine is a neurotransmitter in the brain, and excess circulating histamine disrupts cognitive function [8].
• Headaches and migraines: Mast cells are abundant in the meninges (the membranes surrounding the brain). Their activation releases vasoactive mediators that can trigger migraine-like headaches.
• Anxiety and panic-like episodes: Histamine and other mast cell mediators can produce acute anxiety, a sense of impending doom, or full panic attacks. These episodes can be difficult to distinguish from primary anxiety disorders.
• Insomnia: Histamine promotes wakefulness (which is why antihistamines cause drowsiness). Excess histamine can disrupt sleep onset and maintenance.
• Peripheral neuropathy: Tingling, numbness, or burning sensations in the extremities.

Because mast cell mediators can trigger migraine-like headaches directly, patients with frequent headaches alongside other MCAS symptoms benefit from a dedicated migraine evaluation rather than treating the headaches as a separate, unrelated problem.

Respiratory

• Nasal congestion and rhinitis: Chronic “allergies” that do not respond to typical allergy treatments. Nasal mast cells release histamine in response to irritants, temperature changes, or fragrances.
• Wheezing and shortness of breath: Mast cell mediators cause bronchoconstriction. Some MCAS patients carry an asthma diagnosis for years before MCAS is recognized.
• Throat tightness: A sensation of the throat closing or swelling. This can be alarming and may represent mild laryngeal angioedema.

Musculoskeletal

• Joint and muscle pain: Migratory aches and pains without inflammatory joint disease on testing.
• Bone pain: Mast cell mediators (particularly prostaglandins and cytokines) can cause deep bone aching.

Anaphylaxis and Severe Reactions

At its most extreme, MCAS can cause anaphylaxis or anaphylactoid reactions: sudden onset of hypotension, tachycardia, difficulty breathing, throat swelling, and sometimes loss of consciousness. In MCAS, these severe reactions can occur without a clear IgE-mediated trigger, which is confusing for both patients and emergency physicians [9]. Any patient with recurrent unexplained anaphylaxis should be evaluated for MCAS.

Anyone with a history of these reactions should carry emergency epinephrine and keep a written action plan reviewed with an allergist, since an anaphylactoid episode from MCAS is managed the same way as classic anaphylaxis in the moment, even when the underlying trigger is never identified.

Common MCAS Triggers

One of the defining features of MCAS is that symptoms are triggered by stimuli that should not provoke mast cell degranulation. Common triggers include:

• Temperature extremes: Heat, cold, and rapid temperature changes
• Physical stimuli: Vibration, pressure, friction, exercise, and sunlight
• Emotional stress: Mast cells have receptors for corticotropin-releasing hormone (CRH), connecting them directly to the stress response [10]
• Foods: High-histamine foods (aged cheese, fermented foods, wine, cured meats), alcohol, certain food additives, and individual-specific triggers
• Fragrances and chemicals: Perfumes, cleaning products, paint fumes, and cigarette smoke
• Medications: NSAIDs, opioids, certain antibiotics (vancomycin, fluoroquinolones), contrast dyes, and some anesthetic agents
• Hormonal fluctuations: Many women with MCAS report symptom worsening around menstruation, ovulation, or during perimenopause. Estrogen upregulates mast cell activation.
• Infections: Viral and bacterial infections can trigger prolonged MCAS flares

Toxic mold exposure and chronic infections are two trigger categories that deserve their own workup rather than being lumped in with everyday irritants. Patients whose flares track with a specific building or water-damaged space should read about toxic mold exposure and the broader pattern described in coverage of mold illness and CIRS, since the two conditions are frequently evaluated together. A closer look at common MCAS triggers and how to build an elimination approach around them is often the next practical step once a symptom diary reveals a pattern.

The EDS-POTS-MCAS Triad

Clinicians working with connective tissue disorders have increasingly recognized a triad of co-occurring conditions: hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and MCAS. While the exact mechanism linking all three is still being studied, the overlap is striking [7].

One hypothesis involves connective tissue abnormalities in hEDS affecting the structural support around mast cells, making them mechanically unstable and more prone to degranulation. Mast cell mediators then contribute to autonomic dysfunction (POTS) through their effects on blood vessels and the nervous system. If you have been diagnosed with one of these three conditions and have unexplained symptoms in other systems, screening for the other two is reasonable.

Patients navigating this overlap often do better treating all three conditions as one connected picture rather than three separate referrals. A hypermobile EDS guide and a POTS guide cover the diagnostic path for those two conditions, while a dysautonomia treatment overview describes how the autonomic symptoms shared across the triad are managed day to day.

How MCAS Is Diagnosed

The current consensus diagnostic criteria for MCAS require all three of the following [11]:

1. Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems (skin, GI, cardiovascular, respiratory, neurological).
2. Laboratory evidence of mast cell mediator elevation during or shortly after a symptomatic episode. The most commonly tested markers are serum tryptase (a 20% + 2 ng/mL rise above baseline during an acute episode), 24-hour urine N-methylhistamine, urine prostaglandin D2, and urine leukotriene E4.
3. Symptom improvement with mast cell-targeted therapy (H1 antihistamines, H2 antihistamines, mast cell stabilizers, or leukotriene inhibitors).

In practice, meeting criterion 2 can be challenging. Mast cell mediators are rapidly cleared from the blood (tryptase half-life is about 2 hours), so blood samples drawn hours after a flare may come back normal. Urine testing over 24 hours is often more sensitive than a single blood draw [12].

Practical Diagnostic Tips

• Baseline tryptase should be drawn when you are at your symptom-free best. A second tryptase should be drawn during or within 1-4 hours of a significant flare.
• 24-hour urine collections for prostaglandin D2, N-methylhistamine, and leukotriene E4 should be done during a symptomatic period, not during a quiet phase.
• Avoid antihistamines for 48-72 hours before urine testing if safely possible (this may not be feasible for all patients).
• Refrigerate urine samples during collection (prostaglandins degrade at room temperature).

Because the diagnostic workup can take months and often spans allergy, gastroenterology, and cardiology referrals, many patients find it helpful to read a step by step walkthrough of MCAS diagnosis before their first specialist appointment, so they know which tests to request and when.

How Is MCAS Treated?

MCAS treatment is layered and built around blocking mediator effects and reducing degranulation rather than targeting a single pathway. Most regimens combine several drug classes, then add trigger avoidance and, for some patients, IV support during severe flares.

Medications

• H1 antihistamines: Second-generation agents such as cetirizine, loratadine, or fexofenadine block histamine's effects on skin and blood vessels and are typically the first line of treatment, often at higher than standard allergy doses under physician guidance.
• H2 antihistamines: Famotidine or similar agents block histamine receptors in the gut lining, addressing reflux and acid-related symptoms that H1 blockers do not touch.
• Mast cell stabilizers: Cromolyn sodium and ketotifen reduce degranulation itself rather than blocking mediators after release, though cromolyn's poor oral absorption means benefit can take several weeks to appear.
• Leukotriene inhibitors: Montelukast targets leukotriene-driven symptoms, particularly respiratory and some GI complaints, when antihistamines alone are not enough.
• Low dose naltrexone: Some MCAS-literate physicians prescribe low dose naltrexone off label to modulate immune signaling. Patients considering it often start with a dedicated low dose naltrexone overview and an LDN guide to understand dosing and expectations before raising it with a physician.

Diet and Trigger Management

A low-histamine diet, built around fresh rather than aged or fermented foods, is the most common dietary approach, though it is not supported by large controlled trials and works better for some patients than others. A structured MCAS diet plan, paired with the symptom diary described below, helps identify which specific foods matter for a given patient rather than restricting broadly and indefinitely.

IV Hydration and Supportive Care During Flares

During severe flares, especially when hypotension or dehydration from GI losses is significant, some patients receive IV fluids and electrolytes under medical supervision. Clinics offering IV therapy provide this kind of supportive hydration, and a general IV therapy overview explains what a typical session involves and where the evidence for its use is strongest versus anecdotal. IV support addresses the acute symptoms of a flare; it does not replace mast cell-targeted medication as the core of long-term management.

No medication regimen eliminates MCAS outright, and most patients manage it as a chronic condition with periods of better and worse control rather than a single fix. Evidence for several of these approaches, particularly low dose naltrexone and dietary interventions, remains limited to case series and clinical experience rather than large randomized trials, so expectations should be set accordingly.

Symptom Tracking

Because MCAS symptoms wax and wane and involve multiple systems, a symptom diary is invaluable both for diagnosis and for identifying individual triggers. Track the following:

• Date, time, and duration of each symptom episode
• Which symptoms occurred and their severity (1-10 scale)
• Potential triggers: food intake, environmental exposures, stress, exercise, menstrual cycle timing, weather changes
• Medications taken and their effect on symptoms
• Sleep quality the night before

After 4-6 weeks of tracking, patterns often emerge that are not apparent when symptoms feel random. Many patients discover that their “random” flares actually correlate with specific triggers, hormonal cycles, or cumulative stress loads [13].

When to Seek Evaluation

Consider MCAS evaluation if you have:

• Symptoms spanning two or more organ systems without another clear diagnosis
• Recurrent “allergic” reactions without identifiable IgE-mediated allergies
• Unexplained anaphylaxis or anaphylactoid episodes
• A growing list of food and environmental sensitivities
• A diagnosis of hEDS or POTS with additional unexplained symptoms
• Chronic symptoms that fluctuate in severity and seem to worsen with heat, stress, or certain foods

MCAS-literate allergists, immunologists, and integrative medicine physicians are the most experienced with diagnosis and management. Given the multi-system nature of MCAS, many patients have seen multiple specialists before someone connects the dots.

If chronic fatigue is a dominant feature alongside the symptoms above, it is also worth reading about chronic fatigue syndrome and fibromyalgia, two conditions that share significant symptom overlap with MCAS and are sometimes diagnosed alongside it rather than instead of it.

Frequently Asked Questions

What are the first signs of mast cell activation syndrome?

Early MCAS often shows up as flushing, hives, or itching paired with GI symptoms like cramping, bloating, or diarrhea, sometimes alongside a fast heart rate or lightheadedness when standing. These symptoms tend to come in episodes rather than staying constant, and they often follow a trigger such as heat, exercise, alcohol, or a specific food, which is a key clue that points toward mast cell activation rather than a single-organ diagnosis.

Can MCAS cause brain fog and anxiety?

Yes. Histamine acts as a neurotransmitter in the brain, and excess circulating histamine during a flare can impair concentration, word-finding, and short-term memory while also producing anxiety or panic-like sensations. These neurological symptoms are among the most commonly reported MCAS complaints and can be mistaken for a primary psychiatric or cognitive disorder until the pattern across other organ systems is recognized.

Is MCAS the same as histamine intolerance?

No, though the two overlap and are frequently confused. Histamine intolerance usually reflects reduced activity of the enzyme that breaks down dietary histamine, while MCAS involves mast cells releasing histamine and dozens of other mediators from within the body. A closer look at histamine intolerance explains the distinction and why some patients have both at once.

What triggers an MCAS flare?

Common triggers include temperature extremes, physical stimuli like exercise or vibration, emotional stress, high-histamine foods, fragrances and chemical exposures, certain medications including NSAIDs and some antibiotics, hormonal shifts, and infections. Triggers are highly individual, which is why a symptom diary kept over four to six weeks is usually more useful than a generic avoidance list.

Does mast cell activation syndrome go away on its own?

MCAS is typically a chronic, ongoing condition rather than one that resolves on its own, though symptom severity often responds well to treatment. Most patients manage it long term with antihistamines, mast cell stabilizers, trigger avoidance, and sometimes additional medications like low dose naltrexone, with periods of better and worse control rather than a single fix. Flares can still occur even with a well-managed regimen, which is why ongoing care with an MCAS-literate physician matters.

Related Reading

• Mast Cell Activation Syndrome: Complete Guide
• MCAS Treatment Options
• How MCAS Is Diagnosed
• The MCAS, POTS, and EDS Triad

Sources

1. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163-172. doi:10.1056/NEJMra1409760 ↩
2. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349-355. doi:10.1016/j.jaci.2017.06.007 ↩
3. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. doi:10.1182/blood-2016-09-731893 ↩
4. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10 ↩
5. Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35(5):548-562. doi:10.1016/j.clinthera.2013.04.001 ↩
6. Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152.e2. doi:10.1016/j.jaci.2011.04.037 ↩
7. Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273-297. doi:10.1007/s12016-019-08755-8 ↩
8. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.2016.12.013 ↩
9. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-1104.e4. doi:10.1016/j.jaci.2010.08.035 ↩
10. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015;9:225. doi:10.3389/fnins.2015.00225 ↩
11. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1. doi:10.1016/j.jaip.2019.01.006 ↩
12. Vysniauskaite M, Hertfelder HJ, Oldenburg J, et al. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS One. 2015;10(4):e0124912. doi:10.1371/journal.pone.0124912 ↩
13. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis (Berl). 2021;8(2):137-152. doi:10.1515/dx-2020-0005 ↩